JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

NCT05664971 | Completed Phase 1

• 1 other identifier: JS004-007-Ib/II-LC
• Study Type: interventional
• Target: 119
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with advanced lung cancer

Conditions

Advanced Lung Cancer

Outcome Measures

Primary Outcomes (4)

• Incidence of adverse events (AEs)

  Incidence of adverse events (AEs)

  2 years

• Incidence of SAEs

  Incidence of serious adverse events (SAEs)

  2 years

• Incidence of irAEs

  Incidence of immune-related adverse events (irAEs)

  2 years

• ORR

  Efficacy endpoint: objective response rate (ORR) based on RECIST v1.1 criteria

  2 years

Secondary Outcomes (11)

• DOR

  2 years

• DCR

  2 years

• time to response (TTR)

  2 years

• PFS

  2 years

• OS

  2 years

Study Arms (5)

Cohort 1

EXPERIMENTAL

NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w, maintained until disease progression

Biological: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection; Biological: Toripalimab

Cohort 2

EXPERIMENTAL

NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression

Biological: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection; Biological: Toripalimab; Drug: Docetaxel

Cohort 3

EXPERIMENTAL

NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression

Biological: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection; Biological: Toripalimab; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin

Cohort 4

EXPERIMENTAL

NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Biological: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection; Biological: Toripalimab; Drug: Carboplatin; Drug: Paclitaxel

Cohort 5

EXPERIMENTAL

SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression

Biological: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection; Biological: Toripalimab; Drug: Cisplatin; Drug: Carboplatin; Drug: Etoposide

Interventions

Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection BIOLOGICAL

200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Cohort 1; Cohort 2; Cohort 3; Cohort 4; Cohort 5

Toripalimab BIOLOGICAL

240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Cohort 1; Cohort 2; Cohort 3; Cohort 4; Cohort 5

Docetaxel DRUG

60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression

Cohort 2

Pemetrexed DRUG

500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed

Cohort 3

Cisplatin DRUG

75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Cohort 3; Cohort 5

Carboplatin DRUG

AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Cohort 3; Cohort 4; Cohort 5

Paclitaxel DRUG

175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Cohort 4

Etoposide DRUG

100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles

Cohort 5

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects are eligible for the study if they meet all of the following criteria:
• Sign the informed consent form voluntarily;
• Males or females ≥18 years at the time of signing the informed consent;
• Expected survival ≥3 months;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ;
• Pathologically confirmed locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), which is currently not suitable for local treatment such as radical surgery or radiotherapy; For subjects with non-squamous carcinoma, there is no EGFR sensitive mutation or ALK fusion; for subjects with squamous carcinoma, genetic testing is not mandatory
• Pathologically confirmed extensive-stage small cell lung cancer (ES-SCLC, according to the Veterans Administration Lung Study Group (VALG) staging), previously received no systemic anti-tumor therapy for ES-SCLC (Cohort 5); Subjects with limited-stage SCLC who have previously received systemic anti-tumor therapy cannot be enrolled;
• The subject has at least one measurable lesion as a target lesion (RECIST v1.1 criteria,);
• The subject agrees to provide tumor tissue samples ;
• The subject has good organ function as indicated by screening laboratory results:
• Males of reproductive potential or females of childbearing potential must use effective contraceptive methods during the trial and continue for 6 months after the end of treatment;
• The subject has good compliance and cooperates with the follow-up.

You may not qualify if:

• Subjects who met any of the following criteria will be excluded from the study:
• For the third line and second line populations with advanced lung squamous carcinoma (Cohorts 1 and 2), subjects who have received systemic anti-tumor therapy within 3 weeks before the first dose of study drug, including: chemotherapy, targeted therapy, anti-vascular drug therapy, biological therapy, immunotherapy, radiotherapy or other treatments with investigational products
• Any adverse reactions caused by previous treatments have not recovered to CTCAE (Version 5.0) Grade 1 or below ;
• Symptomatic metastases to central nervous system.;
• Subjects with poorly controlled tumor-related pain who require analgesic treatment must receive the treatment at a stable dose before participating in the study;
• Hydrothorax or ascites or pericardial effusion with clinical symptoms or unstable condition after symptomatic treatment;
• Subjects previously discontinued treatment due to PD-1/PD-L1 inhibitor toxicity;
• Known history of severe allergic reactions to JS004 or toripalimab and its components, scheduled chemotherapeutic drugs and their components;
• Known active or suspected autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease;
• History of interstitial lung disease or drug-induced interstitial lung disease or pulmonitis;
• Received systemic corticosteroids (prednisone \>10 mg/day or equivalent) or other immunosuppressive drugs within 14 days before the first study dose;
• Subjects with a past history of immunodeficiency, including those with other acquired or congenital immunodeficiency diseases, or with a history of organ transplantation, or have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
• Had received live vaccines within 4 weeks before the first study dose;
• Any major surgical procedure within 4 weeks before the first study dose. Planned major surgical procedure to be performed within 30 days after the first dose , or not fully recovered from the previous surgery;
• Suffering from severe cardiovascular and cerebrovascular diseases;

Sponsors & Collaborators

• Shanghai Junshi Bioscience Co., Ltd.: lead

Study Sites (1)

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, 200030, China

Location

MeSH Terms

Interventions

Injections; toripalimab; Docetaxel; Pemetrexed; Cisplatin; Carboplatin; Paclitaxel; Etoposide

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Guanine; Hypoxanthines; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Dicarboxylic; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Coordination Complexes; Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Glucosides; Glycosides; Carbohydrates

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 28, 2022
• First Posted: December 27, 2022
• Study Start: February 9, 2023
• Primary Completion: October 23, 2025
• Study Completion: October 23, 2025
• Last Updated: December 2, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)